Tranexamic acid in patients with intracerebral haemorrhage (STOP-AUST): a multicentre, randomised, placebo-controlled, phase 2 trial
Atte Meretoja, Nawaf Yassi, Teddy Y Wu, Leonid Churilov, Gerli Sibolt, Jiann-Shing Jeng, Timothy Kleinig, Neil J Spratt, Vincent Thijs, Tissa Wijeratne, Der-Yang Cho, Darshan Shah, Geoffrey C Cloud, Phan Thanh, Christopher Bladin, Andrew Moey, Richard I Aviv, Christen D Barras, Gagan Sharma, Chung Y Hsu Show all
The Lancet Neurology | ELSEVIER SCIENCE INC | Published : 2020
BACKGROUND: Despite intracerebral haemorrhage causing 5% of deaths worldwide, few evidence-based therapeutic strategies other than stroke unit care exist. Tranexamic acid decreases haemorrhage in conditions such as acute trauma and menorrhoea. We aimed to assess whether tranexamic acid reduces intracerebral haemorrhage growth in patients with acute intracerebral haemorrhage. METHODS: We did a prospective, double-blind, randomised, placebo-controlled, investigator-led, phase 2 trial at 13 stroke centres in Australia, Finland, and Taiwan. Patients were eligible if they were aged 18 years or older, had an acute intracerebral haemorrhage fulfilling clinical criteria (eg, Glasgow Coma Scale score..View full abstract
Awarded by Australian National Health and Medical Research Council
Awarded by National Health and Medical Research Council-National Heart Foundation Career Development-Future Leader Fellowship
Awarded by Canadian Institutes of Health Research
The study was funded by the Australian National Health and Medical Research Council, grant number 1081718, and the Royal Melbourne Hospital Foundation. NS was supported by a Cofunded National Health and Medical Research Council-National Heart Foundation Career Development-Future Leader Fellowship GNT1110629/100827. RA receives support from Canadian Institutes of Health Research, operating grant 362185.